Cannabis Rescheduling in 2026: What Happens Next and Why It’s Still Not Done

For the first time since the passage of the Controlled Substances Act in 1970, the United States is actively rewriting its federal stance on cannabis.

While cannabis was once firmly categorized as a Schedule I substance, defined as having “no accepted medical use” and a high potential for abuse, it is now moving toward Schedule III, a classification reserved for substances recognized as medically valuable and subject to more moderate regulation.

This shift did not happen overnight. It is the result of years of scientific review, political pressure, public advocacy, and evolving state-level policies. But one moment in particular accelerated the timeline in a meaningful and undeniable way: the executive order issued in late 2025 by President Donald Trump.

That directive did not complete cannabis rescheduling, but it fundamentally changed the pace and seriousness of the process.

Today, cannabis rescheduling is no longer theoretical. It is actively underway. And yet, it remains unfinished; not because momentum has stalled, but because it has entered the most complex and necessary phase of the legal process required to make the change permanent. Let’s dive into this groundbreaking moment in cannabis history and what needs to happen next to complete the rescheduling process.

The Executive Order on Cannabis Rescheduling

When Donald Trump directed federal agencies to expedite cannabis rescheduling, it marked a pivotal turning point in federal cannabis policy. For years, reform had been discussed, studied, and debated. The executive order transformed that conversation into action. It elevated rescheduling from a policy discussion into a federal priority, signaling to agencies that the process should move forward with urgency.

This distinction is critical for understanding the current moment.

The executive order did not, and could not, fully reschedule cannabis on its own. Under U.S. law, drug classification changes must move through a structured administrative process. However, what the order did accomplish was equally important: it removed ambiguity about federal intent and pushed agencies, particularly the Drug Enforcement Administration, to actively advance the entire process.

The executive order accelerated internal reviews, increased coordination between agencies, and ensured that rescheduling was treated as an immediate and serious regulatory objective.

For an issue that had lingered in bureaucratic uncertainty for decades, that shift alone was substantial.

Why Cannabis Rescheduling Takes Time

To understand why cannabis has not yet been officially rescheduled, it is necessary to understand the system governing these decisions.

The Controlled Substances Act was designed to prevent rapid or politically driven changes to drug policy. Instead, it requires a layered process that combines scientific evaluation, legal scrutiny, and public input.

At the center of this process is a scientific and medical review conducted by the U.S. Department of Health and Human Services, working alongside the Food and Drug Administration. In 2023, that review reached a conclusion that marked a historic departure from decades of federal policy: cannabis does have accepted medical use.

That finding alone reshaped the legal foundation of cannabis scheduling.

However, the authority to actually change the classification lies with the Drug Enforcement Administration and the DEA must operate within the framework of federal administrative law. This is where the process becomes slower, but also more durable.

The DEA cannot simply issue a declaration. It must propose a rule, open it to public comment, respond to objections, and ensure that every aspect of the decision can withstand judicial review. In the case of cannabis, this has meant analyzing tens of thousands of public comments, addressing competing legal arguments, and navigating procedural challenges that have delayed hearings and extended timelines. These delays are often interpreted as stagnation, but in reality, they reflect the system functioning as designed.

Once rescheduling is finalized, it will almost certainly face legal challenges, and if the process is not handled correctly, those challenges could overturn the decision entirely.

What Moving to Cannabis to Schedule III Changes

The proposed shift to Schedule III represents one of the most consequential federal policy changes for cannabis in modern history. Unlike Schedule I, which asserts that a substance has no medical value, Schedule III explicitly recognizes accepted medical use. Substances in this category, such as Ketamine, are regulated but widely used in clinical settings.

For cannabis, this change would have immediate and far-reaching implications.

One of the most significant impacts would be financial. Under current law, cannabis businesses are subject to Section 280E of the Internal Revenue Code, which prevents companies dealing in Schedule I substances from deducting standard business expenses. Moving to Schedule III would remove this restriction, fundamentally altering the economic landscape of the cannabis industry.

At the same time, federal recognition of medical use would influence how cannabis is perceived across the healthcare system. Physicians, researchers, and institutions that have historically operated in a gray area would gain a clearer framework for engagement.

Research, in particular, stands to benefit. For decades, cannabis’s Schedule I status has limited clinical studies and slowed scientific progress. Rescheduling would ease many of these restrictions, opening the door to expanded research into therapeutic applications and long-term effects.

What Cannabis Rescheduling Does Not Do

Despite its significance, rescheduling does not equate to legalization. Cannabis would remain a federally controlled substance. Interstate commerce would still face limitations, state and federal law would continue to operate in tension, and criminal enforcement, while likely reduced, would not disappear entirely.

This distinction is important, especially as public expectations continue to evolve.

Rescheduling is best understood as a structural correction, not a final resolution. It aligns federal policy more closely with scientific evidence and state-level realities, but it does not fully reconcile the broader legal landscape.

Congressional Action Continues: The Fair Future Act

While federal agencies work through the rescheduling process, Congress has continued to shape the future of cannabis policy through legislation. Among the most notable efforts is the Fair Future Act, which reflects a shift in focus from classification to equity and industry structure.

Rather than asking whether cannabis should be legal, the bill asks a different question: who benefits from legalization?

The Fair Future Act seeks to expand access for small and minority-owned businesses, address the long-term impacts of prohibition, and ensure that communities disproportionately affected by past enforcement are included in the legal market.

This signals a broader evolution in cannabis policy. Reform is no longer centered solely on legality; it is increasingly focused on fairness, access, and economic participation. And importantly, this legislative momentum is moving forward independently of rescheduling. Lawmakers are not waiting for administrative action to finish before addressing the next phase of reform.

A Defining Moment in Cannabis Policy

What makes this moment historically significant is not just the anticipated outcome, but the way it is unfolding.

Cannabis policy in the United States is being reshaped through a convergence of forces of scientific reassessment, administrative law, executive action, and legislative reform. The executive order from Donald Trump played a critical role in accelerating this process. It did not bypass the system, but it ensured the system moved forward with urgency and purpose.

Now, that process has reached its most technical stage.

The Drug Enforcement Administration must complete its review, resolve procedural challenges, and issue a final rule. Only then will cannabis officially move to Schedule III.

Until that moment, the classification remains unchanged, not because progress has stalled, but because the final steps are still being completed.

Final Thoughts: Progress, Process, and Permanence

Cannabis rescheduling in 2026 represents a rare moment in federal policy, one where long-standing assumptions are being reevaluated in real time.

The executive order provided meaningful momentum. While the scientific review provided justification, and the administrative process is providing legitimacy. Together, they are shaping a policy shift that is not only significant but designed to endure.

When rescheduling is finalized, it will not simply mark a change in classification. It will represent a fundamental shift in how the federal government understands cannabis medically, economically, and legally. And while it has not happened overnight, that is precisely why it will matter for future decades to come.